IL196897A - Preparations based on 1- (3-Chloro-5 - {[4- (4-Chloro-Ophen-2-Il) -5- (4-Cyclohexylpiperazine-1-Il) Thiazole-2-Il] Carbamoyl} Pyridine-2-Il ) Carboxylic acid or salts, to increase levels of human platelet - Google Patents

Preparations based on 1- (3-Chloro-5 - {[4- (4-Chloro-Ophen-2-Il) -5- (4-Cyclohexylpiperazine-1-Il) Thiazole-2-Il] Carbamoyl} Pyridine-2-Il ) Carboxylic acid or salts, to increase levels of human platelet

Info

Publication number
IL196897A
IL196897A IL196897A IL19689709A IL196897A IL 196897 A IL196897 A IL 196897A IL 196897 A IL196897 A IL 196897A IL 19689709 A IL19689709 A IL 19689709A IL 196897 A IL196897 A IL 196897A
Authority
IL
Israel
Prior art keywords
cyclohexylpiperazin
piperadine
chlorothiophen
thiazol
carbamoyl
Prior art date
Application number
IL196897A
Other languages
English (en)
Hebrew (he)
Other versions
IL196897A0 (en
Inventor
Robert E Desjardins
Rudolph Lucek
Original Assignee
Akarx Inc
Robert E Desjardins
Rudolph Lucek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarx Inc, Robert E Desjardins, Rudolph Lucek filed Critical Akarx Inc
Publication of IL196897A0 publication Critical patent/IL196897A0/en
Publication of IL196897A publication Critical patent/IL196897A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL196897A 2006-08-08 2009-02-04 Preparations based on 1- (3-Chloro-5 - {[4- (4-Chloro-Ophen-2-Il) -5- (4-Cyclohexylpiperazine-1-Il) Thiazole-2-Il] Carbamoyl} Pyridine-2-Il ) Carboxylic acid or salts, to increase levels of human platelet IL196897A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83633406P 2006-08-08 2006-08-08
PCT/US2007/017860 WO2008021283A2 (en) 2006-08-08 2007-08-08 Compositions and methods for increasing blood platelet levels in humans

Publications (2)

Publication Number Publication Date
IL196897A0 IL196897A0 (en) 2011-08-01
IL196897A true IL196897A (en) 2015-08-31

Family

ID=39082656

Family Applications (4)

Application Number Title Priority Date Filing Date
IL196897A IL196897A (en) 2006-08-08 2009-02-04 Preparations based on 1- (3-Chloro-5 - {[4- (4-Chloro-Ophen-2-Il) -5- (4-Cyclohexylpiperazine-1-Il) Thiazole-2-Il] Carbamoyl} Pyridine-2-Il ) Carboxylic acid or salts, to increase levels of human platelet
IL240323A IL240323A (en) 2006-08-08 2015-08-03 Preparations based on 1 - (3-chloro-5 - {[4- (4-chloro-phenyl-2-ram) -5- (4-cyclohexylpiperazine-1-ram) thiazole-2-ram] carbamoyl} pyridine-2-ram ) Carboxylic acid or salts, to increase levels of human platelet
IL240322A IL240322A0 (en) 2006-08-08 2015-08-03 Preparations based on 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazio-1-yl)thiazol-2-yl]carbamoyl}pyridin-2-yl Piperadine-4-carboxylic acid or salts, to increase levels of platelets in human blood
IL245911A IL245911A0 (en) 2006-08-08 2016-05-29 Compositions and methods for increasing the level of blood platelets in humans

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL240323A IL240323A (en) 2006-08-08 2015-08-03 Preparations based on 1 - (3-chloro-5 - {[4- (4-chloro-phenyl-2-ram) -5- (4-cyclohexylpiperazine-1-ram) thiazole-2-ram] carbamoyl} pyridine-2-ram ) Carboxylic acid or salts, to increase levels of human platelet
IL240322A IL240322A0 (en) 2006-08-08 2015-08-03 Preparations based on 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazio-1-yl)thiazol-2-yl]carbamoyl}pyridin-2-yl Piperadine-4-carboxylic acid or salts, to increase levels of platelets in human blood
IL245911A IL245911A0 (en) 2006-08-08 2016-05-29 Compositions and methods for increasing the level of blood platelets in humans

Country Status (8)

Country Link
US (2) US20080039475A1 (enExample)
EP (2) EP2452674B1 (enExample)
JP (3) JP2010500361A (enExample)
AU (2) AU2007284644B2 (enExample)
CA (1) CA2660283C (enExample)
ES (2) ES2452032T3 (enExample)
IL (4) IL196897A (enExample)
WO (1) WO2008021283A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1466912T1 (sl) * 2002-01-18 2013-08-30 Astellas Pharma Inc. Derivat 2-acilaminotiazola ali njegova sol
JP2013501811A (ja) * 2009-08-14 2013-01-17 エーザイ インコーポレーテッド 血小板産生を刺激するためのｅ５５０１の使用
CN112022825B (zh) * 2020-08-24 2024-03-22 瑞阳制药股份有限公司 马来酸阿伐曲泊帕片剂及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5256675A (en) * 1989-08-07 1993-10-26 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same
IE68593B1 (en) * 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
EP0620403B1 (de) * 1993-04-08 1996-12-04 ABB Management AG Misch- und Flammenstabilisierungseinrichtung in einer Brennkammer mit Vormischverbrennung
ATE246686T1 (de) * 1995-03-09 2003-08-15 Kyowa Hakko Kogyo Kk Pyrrolocarbazolderivate
AU700837B2 (en) * 1995-04-28 1999-01-14 Banyu Pharmaceutical Co., Ltd. 1,4-di-substituted piperidine derivatives
IL122102A (en) * 1995-06-07 2002-07-25 Glaxo Group Ltd Peptides and compounds that bind to a thrombopoietin receptor, pharmaceutical compositions comprising them and their use as medicaments
US5963666A (en) * 1995-08-18 1999-10-05 International Business Machines Corporation Confusion matrix mediated word prediction
US6040335A (en) * 1995-10-17 2000-03-21 Suntory Limited Therapeutics for thrombocytopenia
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
JP2002526482A (ja) * 1998-09-18 2002-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
AU1732900A (en) * 1998-11-17 2000-06-05 Ligand Pharmaceuticals Incorporated Methods of treating thrombocytopenia
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1364949A4 (en) * 2001-02-02 2005-11-23 Takeda Pharmaceutical JNK INHIBITOR
JPWO2002062775A1 (ja) * 2001-02-02 2004-06-10 山之内製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
SI1466912T1 (sl) * 2002-01-18 2013-08-30 Astellas Pharma Inc. Derivat 2-acilaminotiazola ali njegova sol
BR0312023A (pt) * 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
AU2003268687A1 (en) 2002-09-30 2004-04-19 Yamanouchi Pharmaceutical Co., Ltd. Novel salt of 2-acylaminothiazole derivative
CA2523125A1 (en) * 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
MXPA06000441A (es) * 2003-07-17 2006-04-05 Astellas Pharma Inc Derivado de 2-acilaminotiazole o sal del mismo.
ES2599529T3 (es) * 2003-08-12 2017-02-02 Shionogi & Co., Ltd. Compuestos que tienen agonismo hacia el receptor de trombopoyetina
KR20080074166A (ko) * 2005-11-08 2008-08-12 아스테라스 세이야쿠 가부시키가이샤 혈소판감소증을 치료하는 조성물 및 방법

Also Published As

Publication number Publication date
WO2008021283A2 (en) 2008-02-21
EP2452674B1 (en) 2014-03-26
IL196897A0 (en) 2011-08-01
AU2011253775A1 (en) 2011-12-22
EP2056826A4 (en) 2009-09-09
AU2007284644B2 (en) 2011-09-01
ES2470333T3 (es) 2014-06-23
EP2056826B1 (en) 2014-01-08
AU2007284644A1 (en) 2008-02-21
EP2056826A2 (en) 2009-05-13
IL240322A0 (en) 2015-09-24
IL240323A (en) 2016-05-31
EP2452674A2 (en) 2012-05-16
US20080039475A1 (en) 2008-02-14
JP6258264B2 (ja) 2018-01-10
JP2013047257A (ja) 2013-03-07
ES2452032T3 (es) 2014-03-31
JP2010500361A (ja) 2010-01-07
AU2011253775B2 (en) 2014-02-13
WO2008021283A3 (en) 2008-12-11
JP2015221806A (ja) 2015-12-10
CA2660283A1 (en) 2008-02-21
HK1170673A1 (en) 2013-03-08
IL245911A0 (en) 2016-07-31
EP2452674A3 (en) 2012-05-30
CA2660283C (en) 2014-11-18
US20110224226A1 (en) 2011-09-15
IL240323A0 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
NO2020032I1 (no) Avatrombopag and pharmaceutically acceptable salts thereof, particularly avatrombopag maleate (1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl) thiazol-2-yl] carbamoyl} pyridin-2-yl) piperidine-4-carboxylic acid maleic acid salt
IL199152A (en) Annals 2 - (piperidine-4-ram) -4-phenoxy or phenylamino-pyrimidine, containing and containing pharmaceutical preparations for the preparation of viral infections
MX2009013272A (es) Formas amorfas estabilzadas de mesilato de imatinib.
TN2009000317A1 (en) Solid preparation comprising alogliptin and pioglitazone
CL2008000750A1 (es) Metodo para la administracion de una dosis semanal de 2-[6-(3-amino-piperidin-1-il)3-metil-2,4 dioxo-3,4 dihidro-2h-pirimidin-1-il metil]-4 fluoro-benzonitrilo; composicion farmaceutica de una forma de dosificacion individual de dicho compuesto; y su
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
MXPA05013637A (es) Inhibidores gsk-3 y usos de los mismos.
WO2007093450A3 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
IL194744A (en) Derivatives 1– (alkyl) –3– (amino-converted) –5– (converted) - s-triazole, a process for their preparation and pharmacological preparations containing them for the treatment of psychotic diseases
WO2009007411A3 (fr) Inhibition de la formation des ages
WO2009150118A3 (en) Novel salts of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid
BR112012003462A2 (pt) "composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase."
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
NZ594556A (en) Carboxamide compounds and methods for using the same
WO2007116025A3 (en) Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
WO2010090494A3 (ko) 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
IL240323A (en) Preparations based on 1 - (3-chloro-5 - {[4- (4-chloro-phenyl-2-ram) -5- (4-cyclohexylpiperazine-1-ram) thiazole-2-ram] carbamoyl} pyridine-2-ram ) Carboxylic acid or salts, to increase levels of human platelet
MX2015017058A (es) Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos.
IL201959A (en) Annals 2 - (1-Acetyl-Piperidine-4-Il) -4,2- Dihydro-Pyrazole-3-On
WO2011098799A3 (en) Respiratory disease treatment
EA201000701A1 (ru) 4-[4-(2-адамантилкарбамоил)-5-трет-бутилпиразол-1-ил]бензойная кислота-465
WO2007104933A8 (en) Chemical compounds
TW200800993A (en) Organic compounds
MX337606B (es) Metodo y composiciones farmaceuticas para el tratamiento de la hiperglicemia postprandial de la diabetes tipo ii, a traves de la mucosa bucal.
WO2009136884A3 (en) Metformin-pioglitazone formulation with antihyperglycemic effects

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed